For following the competition: what moved in each program, several studies read as one move.
- IM96
- ZM001
- Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Imunopharm Technology to watchlistEvery Monday by email · turn it off any timePro · free during the beta